The Science and Ethics of Induced Pluripotency: What Will Become of Embryonic Stem Cells?

Zacharias, David G.; Nelson, Timothy J.; Mueller, Paul S.; Hook, C. Christopher

doi:10.4065/mcp.2011.0054

Cited by 49 publications

(33 citation statements)

References 79 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although recent reports suggest that hESCs are derived more efficiently from high-quality embryos, it is difficult to obtain good-quality human embryos for hESC derivation [21,22]. However, the usage of embryos and derivation of hESCs for research has resulted in polarized ethical debates with most of the controversy centered on embryo destruction [6,23]. Therefore, these abnormal fertilized zygotes, which are destined to be discarded from IVF cycles, are alternative resources for hESC production.…”

Section: In Vitro and In Vivo Differentiation Potential Of The Hesc Linementioning

confidence: 99%

Triploid and diploid embryonic stem cell lines derived from tripronuclear human zygotes

Chen

Luo

Fan

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Human embryonic stem cells (hESCs) are selfrenewing, pluripotent cells that are valuable research tools and hold promise for use in regenerative medicine. The need for new hESC lines motivated our attempts to find a new resource for the derivation of hESC lines. The aim of this work was to establish more hESC lines from abnormal fertilized zygotes and to meet the emerging requirements for their use in cell replacement therapies, disease modeling, and basic research. Methods A total of 130 tripronuclear human zygotes was collected 18-20 h post-insemination and cultured in a modified culture medium. The inner cell mass of 12 blastocysts were isolated by a mechanical method in order to establish embryonic stem cell lines. Results We established four hESC lines derived from 130 trinuclear zygotes, one of which was triploid and the others were diploid. The efficiency of deriving hESC lines is 3.08%. The ratio of deriving triploid and diploid hESC lines is 1:3. All of these hESC lines exhibited similar markers of undifferentiated hESCs and had the typical morphology of hESCs, a capacity for long-term proliferation, and pluripotent differentiation potential both in vivo and in vitro.Conclusions These abnormal zygotes, which otherwise would have been discarded, can serve as an alternative source for normal euploid hESC lines.

show abstract

Section: In Vitro and In Vivo Differentiation Potential Of The Hesc Linementioning

confidence: 99%

Triploid and diploid embryonic stem cell lines derived from tripronuclear human zygotes

Chen

Luo

Fan

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…tHe science and etHics of induced pluRipotency In the current issue of Mayo Clinic Proceedings, Zacharias et al 17 highlight the science and ethics underlying induced pluripotency and underscore that nuclear reprogramming offers a revolutionary strategy for embryo-independent derivation of pluripotent stem cells from somatic adult sources. Development of reprogramming techniques leading to iPS generation has dramatically changed the landscape of stem cell research and its applications.…”

Section: Stem Cells In Our Bodiesmentioning

confidence: 99%

“…In particular, partial programming can result in transformed or dysplastic progenitor cells, which can contaminate derived stem cell pools. 17 Producing safe and highly purified iPS is paramount for clinical applications. The ultimate value of iPS technology for transplant therapy will depend on ensuring reprogramming fidelity with normal genetic and epigenetic status and defined immunotolerance.…”

Section: Stem Cells In Our Bodiesmentioning

confidence: 99%

“…Moreover, the availability of reprogrammed cells as a possible source for autologous pluripotent stem cell transplant may eliminate, at least in principle, the need for immunosuppression in the context of cell therapy. 17 Of note, derivation of iPS requires a routine punch biopsy and an established methodology for coerced expression of a small number of defined transcription factors to trigger reprogramming, offering a virtually unlimited renewable pool of new tissues obtained from the patient's own cells. In this way, at Mayo Clinic, iPS have been bioengineered for experimental cardiovascular treatments, 18,19 as well as for derivation of glucose-responsive insulin-secreting human cell progeny.…”

Section: Stem Cells In Our Bodiesmentioning

confidence: 99%

See 1 more Smart Citation

Regenerative Medicine: On the Vanguard of Health Care

Terzic

Folmes

Martinez‐Fernandez

et al. 2011

Mayo Clinic Proceedings

View full text Add to dashboard Cite

“…2 This transformative development has alleviated the need to compromise between easy access to adult, multipotent stem cells, and truly pluripotent, but ethically contentious, embryonic stem cells (ESCs). 6,7 Since 2006, reprogramming methods have markedly improved, as have the differentiation protocols for creating mature cell types. [8][9][10] Today, iPS cells are vector-free and can be routinely derived from various tissues (skin, blood, and many others) of healthy individuals and patients with genetic mutations.…”

Section: Area I: Pscs: Understanding and Exploiting Pluripotencymentioning

confidence: 99%